Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, ...

Comparatively, PDAC with lung metastasis is associated with active tumor immunity that may contribute to better median overall survival (OS) rates as compared to those who develop liver metastases.

In a new study, researchers at the University of California San Diego School of Medicine have discovered that an enzyme called MICAL2 promotes tumor growth and spread in pancreatic ductal ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form ... and spread in pancreatic ductal adenocarcinomas (PDAC), the most common form of pancreatic cancer.

Due to the high rate of metastasis, five-year survival is extremely low and treatment options are limited. Even within pancreatic cancer there are specific subtypes, which direct physicians on what ...

"Encouraging tumor response rates observed in an earlier cohort ... 1/2 GOBLET study is designed to evaluate newly diagnosed metastatic PDAC patients treated with pelareorep + mFOLFIRINOX with ...

"Encouraging tumor response rates observed in an earlier cohort of the GOBLET study underscore ... About GOBLET Cohort 5 The mFOLFIRINOX cohort of the Phase 1/2 GOBLET study is designed to evaluate ...

A total of 43 patients with CLDN18.2-positive advanced PDAC (≥60% tumor cells with membranous staining intensity ≥1+ by IHC) received IBI343 6 mg/kg Q3W monotherapy. All participants had previously ...